Listed

Mesa Laboratories Inc: Form 10-Q for the period ended Dec 31, 2020

Filed with the SEC on Feb 3, 2021 and accepted by EDGAR at Feb 3, 2021, 08:01 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2020-10-01 to 2020-12-31$34.2mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2020-04-01 to 2020-12-31$96.0mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2020-10-01 to 2020-12-31$13.5mus-gaap:CostOfRevenue
Cost of revenue9 months2020-04-01 to 2020-12-31$33.7mus-gaap:CostOfRevenue
Gross profit3 months2020-10-01 to 2020-12-31$20.7mus-gaap:GrossProfit
Gross profit9 months2020-04-01 to 2020-12-31$62.3mus-gaap:GrossProfit
Research and development3 months2020-10-01 to 2020-12-31$2.7mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2020-04-01 to 2020-12-31$7.7mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2020-10-01 to 2020-12-31$22.0kus-gaap:OperatingIncomeLoss
Operating income9 months2020-04-01 to 2020-12-31$8.1mus-gaap:OperatingIncomeLoss
Interest expense3 months2020-10-01 to 2020-12-31$1.9mus-gaap:InterestExpense
Interest expense9 months2020-04-01 to 2020-12-31$5.8mus-gaap:InterestExpense
Income tax3 months2020-10-01 to 2020-12-31−$1.2mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2020-04-01 to 2020-12-31−$1.9mus-gaap:IncomeTaxExpenseBenefit
Diluted EPS3 months2020-10-01 to 2020-12-31−$0.89us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2020-04-01 to 2020-12-31−$0.13us-gaap:EarningsPerShareDiluted
Basic EPS3 months2020-10-01 to 2020-12-31−$0.89us-gaap:EarningsPerShareBasic
Basic EPS9 months2020-04-01 to 2020-12-31−$0.13us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2020-10-01 to 2020-12-315,125,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2020-04-01 to 2020-12-314,922,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2020-04-01 to 2020-12-31$23.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2020-04-01 to 2020-12-31$954.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid9 months2020-04-01 to 2020-12-31$2.3mus-gaap:PaymentsOfDividends
Cash and equivalentsAt period end2020-12-31$253.7mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-12-31$295.3mus-gaap:AssetsCurrent
Total assetsAt period end2020-12-31$621.6mus-gaap:Assets
Current liabilitiesAt period end2020-12-31$27.8mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-12-31$208.8mus-gaap:Liabilities
Shareholders' equityAt period end2020-12-31$412.8mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001437749-21-001796. Last ingested by Listed: Nov 13, 2026, 07:45 ET. Listed shows no prices and gives no investment advice.